GTB-3550 Shows Early Efficacy as MDS and AML Therapy

Retrieved on: 2021-04-13 22:52:30

Tags for this article:

Click the tags to see associated articles and topics

GTB-3550 Shows Early Efficacy as MDS and AML Therapy. View article details on hiswai:

Excerpt

... myelodysplastic syndromes (MDS) and refractory/relapsed (R/R) acute myeloid leukemia (AML), according to a press release by GT Biopharma, Inc.

Article found on: www.targetedonc.com